{"id":2881,"date":"2020-12-21T12:01:54","date_gmt":"2020-12-21T20:01:54","guid":{"rendered":"https:\/\/depts.washington.edu\/pandemicalliance\/?p=2881"},"modified":"2020-12-22T12:05:02","modified_gmt":"2020-12-22T20:05:02","slug":"broad-cross-national-public-support-for-accelerated-covid-19-vaccine-trial-designs","status":"publish","type":"post","link":"https:\/\/depts.washington.edu\/pandemicalliance\/2020\/12\/21\/broad-cross-national-public-support-for-accelerated-covid-19-vaccine-trial-designs\/","title":{"rendered":"Broad Cross-National Public Support for Accelerated COVID-19 Vaccine Trial Designs"},"content":{"rendered":"<p>Results from a cross-national survey conducted in Australia, Canada, Hong Kong, New Zealand, South Africa, Singapore, the UK, and the US in May 2020 (n\u00a0=\u00a05920) showed that most respondents preferred for scientists to conduct accelerated trials (human challenge trials, 75%; Phase II\/III safety, immunogenicity, and efficacy integrated trials, 63%) over traditional vaccine trials for COVID-19. Respondents were presented with hypothetical studies, and generally understood the key differences and ethical trade-offs between the designs. This support was consistent across geographic and demographic subgroups.<\/p>\n<p><i>Broockman et al. (Dec 14, 2020). Broad Cross-National Public Support for Accelerated COVID-19 Vaccine Trial Designs. Vaccine. <\/i><a href=\"https:\/\/doi.org\/10.1016\/j.vaccine.2020.11.072\">https:\/\/doi.org\/10.1016\/j.vaccine.2020.11.072<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Results from a cross-national survey conducted in Australia, Canada, Hong Kong, New Zealand, South Africa, Singapore, the UK, and the US in May 2020 (n\u00a0=\u00a05920) showed that most respondents preferred for scientists to conduct accelerated trials (human challenge trials, 75%; Phase II\/III safety, immunogenicity, and efficacy integrated trials, 63%) over traditional vaccine trials for COVID-19&#8230;.<\/p>\n<div><a class=\"more\" href=\"https:\/\/depts.washington.edu\/pandemicalliance\/2020\/12\/21\/broad-cross-national-public-support-for-accelerated-covid-19-vaccine-trial-designs\/\">Read more<\/a><\/div>\n","protected":false},"author":7,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[6],"tags":[33],"topic":[31],"class_list":["post-2881","post","type-post","status-publish","format-standard","hentry","category-article-summary","tag-vaccines","topic-vaccines-and-immunity"],"_links":{"self":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/2881","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/comments?post=2881"}],"version-history":[{"count":1,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/2881\/revisions"}],"predecessor-version":[{"id":2882,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/2881\/revisions\/2882"}],"wp:attachment":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/media?parent=2881"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/categories?post=2881"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/tags?post=2881"},{"taxonomy":"topic","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/topic?post=2881"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}